Abstract
The impact of renal insufficiency on the dispositions of 300 mg of orally administered ceftibuten-cis, a new broad-spectrum oral cephalosporin, and its primary metabolite ceftibuten-trans was characterized in 30 adult subjects. Subjects were divided into five groups of six subjects each on the basis of their 24-h ambulatory creatinine clearances (CLCR). The apparent total body clearance (CLP/F; where F is absolute bioavailability) and renal clearance of ceftibuten-cis were significantly lower in subjects with end-stage renal disease (on maintenance hemodialysis; group V) and in those with severe (CLCR, 5 to 29 ml/min; group IV) and moderate (CLCR, 30 to 49 ml/min; group III) renal insufficiency than in those with mild renal insufficiency (CLCR, 50 to 80 ml/min; group II) or normal renal function (CLCR, greater than 80 ml/min; group I). A significant correlation was observed between CLCR and ceftibuten-cis CLP/F. The mean apparent steady-state volume of distribution (V beta/F) of ceftibuten-cis ranged from 0.21 to 0.24 liter/kg in subjects in group I, II, III, and IV. V beta/F was significantly greater in the group V subjects with end-stage renal disease (V beta/F, 0.39 +/- 0.27 liters/kg). These changes in V beta/F cannot be separated from possible changes in bioavailability. The maximum concentration of ceftibuten-trans in plasma was significantly higher and occurred significantly later in group IV subjects than it did in subjects in the other groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barr W. H., Lin C. C., Radwanski E., Lim J., Symchowicz S., Affrime M. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):93–100. doi: 10.1016/0732-8893(91)90096-x. [DOI] [PubMed] [Google Scholar]
- Bianchetti G., Graziani G., Brancaccio D., Morganti A., Leonetti G., Manfrin M., Sega R., Gomeni R., Ponticelli C., Morselli P. L. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet. 1976;1(5):373–384. doi: 10.2165/00003088-197601050-00004. [DOI] [PubMed] [Google Scholar]
- Drusano G. L. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother. 1988 Mar;32(3):289–297. doi: 10.1128/aac.32.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gibson T. P., Giacomini K. M., Briggs W. A., Whitman W., Levy G. Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin Pharmacol Ther. 1980 May;27(5):665–670. doi: 10.1038/clpt.1980.94. [DOI] [PubMed] [Google Scholar]
- Gibson T. P. Principles of drug dose adjustment during hemodialysis. Am J Kidney Dis. 1983 Sep;3(2):111–113. doi: 10.1016/s0272-6386(83)80024-9. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Barry A. L. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines. Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):802–807. doi: 10.1007/BF01975055. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Barry A. L. In-vitro antimicrobial activity of 7432-S (SCH39720) against commonly isolated respiratory tract pathogens. J Antimicrob Chemother. 1988 Sep;22(3):387–389. doi: 10.1093/jac/22.3.387-a. [DOI] [PubMed] [Google Scholar]
- Riggs D. S., Guarnieri J. A., Addelman S. Fitting straight lines when both variables are subject to error. Life Sci. 1978 Apr 3;22(13-15):1305–1360. doi: 10.1016/0024-3205(78)90098-x. [DOI] [PubMed] [Google Scholar]